Renalytix Share Discussion Threads

[wan] 16/6/2019 05:17

Good coverage in the Mail on Sunday -

MIDAS SHARE TIPS: The diagnosis?
Renalytix is a healthy investment free from Woodford Disease

By JOANNE HART,

PUBLISHED: 21:02, 15 June 2019

City brokers have high hopes for Renalytix. The company is forecast to deliver revenues of $3.7 million in the year to June 2020, soaring to $19 million in 2021. Currently loss-making, the firm is expected to become profitable from 2021 if not earlier.

Although KidneyIntelX will start out in America, Baines and McCullough have the UK and Continental Europe in their sights. They have also started work on another diagnostic product, to improve kidney transplant results.

Full story -

[wan] 13/6/2019 07:24

Some interesting tweets in the last few days -

[volsung] 07/6/2019 12:45

Bought a few. Big spread

[ileeman] 07/6/2019 08:20

I bought on earlier in the week, great news today.

300p soon?

[wan] 07/6/2019 07:54

There is certainly momentum behind the progress Renalytix is making as the good news continues!

Renalytix is shaping up to become the partner of choice across the entire spectrum in the management of kidney disease....which will surely be of increasing interest to pharma (e.g. Janssen, to name but one).

Of course FDA recommendation will play an important part, as evidenced last year
with a record number of FDA approvals of new drugs with biomarker strategies referenced in their labels.

[sspurt] 04/6/2019 15:22

Don't think N+1 Singer have published a price target. EPS of 4.7c for 12m to 06/21 is their current forecast but suspect it is total finger in the wind.

[fardistanthills] 04/6/2019 11:46

Thx - & thx too for all your posting here.

[wan] 04/6/2019 11:35

If there are, I haven't seen any!

[fardistanthills] 04/6/2019 11:00

Ah OK thanks, I'm with ii and having been able to buy RENX with them - they must be able to differentiate between UK / US citizens (Or exclude US citizens?) It is something which has passed me by.

Are there any share price targets kicking about for RENX yet - broker, etc?

[wan] 04/6/2019 09:01

FDH...Unlike other investment platforms, Barclays Smart Investor decided to not differentiate between a US citizen and a UK citizen. Thus, this situation prevents Barclays UK clients (UK citizens) from purchasing certain shares. This is to comply with Regulation S which is a restriction under the US Securities Act preventing US investors from purchasing shares. So Barclays are saying that in order to comply with Regulation S, their decision was to restrict buy trading for 'all' of their clients. In this case preventing purchasing of shares in Renalytix!

[fardistanthills] 04/6/2019 08:37

Hi wan, could you please explain "Shame on Barclays for not allowing UK investors to increase exposure/take part" "increase exposure/take part" in what? Only bought into RENX a few weeks back. Thanks in anticipation. FDH

[wan] 04/6/2019 07:50

Another key milestone achieved for scaled commercial test production as we approach commercial launch of KidneyIntelX(TM), which is expected in the of 2019.

It is refreshing to see a company routinely delivering upon what they stated in terms of both milestones and timescales.......long may that continue!

Shame on Barclays for not allowing UK investors to increase exposure/take part!!!

[wan] 28/5/2019 07:40

Another welcome update as we advance towards commercial operation.

[wan] 24/5/2019 07:36

Renalytix tweeted to highlight that U.S. FDA Grants Priority Review of INVOKANA® (canagliflozin) sNDA for the Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes.

The FDA grants Priority Review to medicines that may offer significant improvements in the treatment, diagnosis or prevention of a serious condition. This designation shortens the review period to six months compared to 10 months for Standard Review.

If approved, INVOKANA® will be the first and only therapy in nearly 20 years indicated to reduce the risk of kidney failure when added to current standard of care


Application was submitted in March 2019 based on landmark phase 3 CREDENCE renal outcomes study published in the New England Journal of Medicine

Raritan, NJ (May 22, 2019) –
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the supplemental New Drug Application (sNDA) for INVOKANA® (canagliflozin) to reduce the risk of end-stage kidney disease (ESKD), the doubling of serum creatinine, and renal or cardiovascular (CV) death in adults with type 2 diabetes (T2D) and chronic kidney disease (CKD). If approved for this new indication, INVOKANA® will be the first and only diabetes medicine to treat CKD in patients with T2D.

Full release -

[wan] 21/5/2019 07:34

Today's news regarding the expansion of FractalDx core investigator group is perhaps put into better perspective by the fact that the investigator group has doubled in size!

With clinical validation for the first diagnostic product from the portfolio beginning in the second half of 2019, there is certainly a focusing of expert minds.

[wan] 20/5/2019 08:10

Persistent Systems
Published on 14 May 2019

Developing new solutions to treat kidney disease proactively, it’s essential for RenalytixAI to bring their products to market faster. As CTO and co-founder, Fergus Fleming says, “Working with a company that has the scale and breadth of Persistent, we can bring two key aspects together; data science and AI capabilities, coupled with the development of complex and integrated software solutions which come together with our products.” Watch video to learn more.

[the stigologist] 16/5/2019 12:15

Physiomics are on a mission today in terms of tweets and their first ever blog post explaining their Virtual Tumour model

(coincides (coincidentally?) with major news carried on BBC etc about their partners/collaborators ICR (Institute of Cancer Research) launching £75m new cancer breakthrough treatments centre
).

Tweet :-

Blog post :-


Reminder :

PYC Mkt Cap £3m (Rev £0.5m)
RENX Mkt Cap £100m (Rev £0m)
SENS Mkt Cap £200m (Rev £0m)

[wan] 14/5/2019 08:22

New Study Finds Chronic Kidney Disease Remains Largely Undiagnosed in Nearly Half of Patients with Type 2 Diabetes and Chronic Kidney Disease
Worldwide, 160 million people with type 2 diabetes (T2D) are at risk for developing chronic kidney disease (CKD)1


Study underscores the need for increased education focused on diagnosing and treating patients with T2D and CKD

May 10, 2019 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results of a new, retrospective, observational study showing 49 percent of patients with type 2 diabetes (T2D) and lab-confirmed chronic kidney disease (CKD) did not have a CKD diagnosis from their doctor in a claims database. The 123,000-patient study, titled Prevalence and Factors Associated with Undiagnosed Chronic Kidney Disease in Diabetes Mellitus, was presented this week at the National Kidney Foundation (NKF) 2019 Spring Clinical Meetings in Boston, Mass.

Full release -

[9degrees] 10/5/2019 15:33

post 41 thanks wan

[wan] 10/5/2019 07:40

Renalytix tweeted the following (15 hours ago) -

Dr. Coca gave a talk on "Optimizing Drug Development via Progressive Disease Enrichment of Clinical Trial Populations" at CKD-3 summit on May 7th. After his talk, Dr. Aliza Thompson of the FDA commented and agreed that continuous risk scores should be employed for enrichment.


It's also worth browsing the agenda's -

May 6-8
Boston, MA, USA

The 2nd Chronic Kidney Disease Drug Development (CKD3) focuses on demonstrating greater therapeutics efficacy than the current standard of care.

Now including FDA and analysis of the CREDENCE trial by Janssen R&D *
Chronic Kidney Disease Drug Development (CKD3) focuses exclusively on overcoming challenges limiting the development of more efficacious and disease-modifying drugs against diabetic nephropathy, genetic and glomerular kidney disease.

Incorporating insights from 32 world class experts including regulatory updates from the FDA, and analysis of the results from CREDENCE by Janssen R&D; this uniquely specific forum assesses key clinical and translational hurdles and the hottest emerging research necessary to achieve the potential of next-generation CKD drugs.

[wan] 10/5/2019 05:18

9Degrees...Apparently' it's because when the shares were listed they were unavailable to US investors (Regulation F I think). This should not ordinarily be a problem (if you are not a US citizen), however, Barclays Smart Investor platform cannot distinguish a buyers nationality and thus the platform (arguably a Barclays decision!) does not allow purchases in Renalytix (which is perverse that we ended up with the stock and can sell via Barclays). This is very poor indeed, because they should be able to tell an individuals nationality given the information required and held, and it's a 'very' frustrating situation to say the least!

I have escalated the situation to an official complaint!

[9degrees] 07/5/2019 16:27

on Barclays smartinvestor can only sell but not buy. Why not Barclays ???

[the stigologist] 07/5/2019 15:41

UK leads the field in Healthcare/Biotech/Pharma AI/Machine Learning

Unlisted entities

Google Deepmind $500m+
Benevolent AI $2000m+
ExScientia $1000m+

Listed entities

#RENX £90m
#SENS £230m
#PYC £2m

Physiomics is undervalued by multiples. Only a matter of time before a moonshoot


News today re ExScientia :-